Image pharmaphorum Editor Views & Analysis Data hackathon analyses truth behind TB vaccine and COVID-19 Is a century-old vaccine a ‘game-changer’ for COVID-19? Views & Analysis What HCPs Think about schools reopening In our latest article in the What HCPs Think series, CREATION.co’s Jamie Doggett analyses the soc Views & Analysis Toxic positivity and grief: The reality of living through ca... Cancer doesn’t end when treatment stops – it’s a lifelong journey and people need support throughout, says patient advocate Megan-Claire Chase. Sales & Marketing Time to change the channel? The future for customer engageme... Sarah Rickwood delves into IQVIA data to find out exactly how pharma's HCP engagement has changed over COVID-19, and what the channel mix might look like after the pandemic. Load more results
Views & Analysis Data hackathon analyses truth behind TB vaccine and COVID-19 Is a century-old vaccine a ‘game-changer’ for COVID-19?
Views & Analysis What HCPs Think about schools reopening In our latest article in the What HCPs Think series, CREATION.co’s Jamie Doggett analyses the soc
Views & Analysis Toxic positivity and grief: The reality of living through ca... Cancer doesn’t end when treatment stops – it’s a lifelong journey and people need support throughout, says patient advocate Megan-Claire Chase.
Sales & Marketing Time to change the channel? The future for customer engageme... Sarah Rickwood delves into IQVIA data to find out exactly how pharma's HCP engagement has changed over COVID-19, and what the channel mix might look like after the pandemic.
News Senju launches first-in-class dry eye disease drug in Japan Senju has launched a new drug for dry eye disease (DED) in Japan, Avarept, the first drug in the TRPV1 antagonist class to reach the market.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
